CLSI Publishes Second Edition of M24S—Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes
March 31, 2023
The Clinical and Laboratory Standards Institute (CLSI) has published M24S—Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes, 2nd Edition. M24S includes the minimal inhibitory concentrations and QC ranges developed following the standards described in CLSI document M24, which includes susceptibility testing procedures for Mycobacterium tuberculosis complex (MTBC), clinically significant slowly and rapidly growing mycobacterial species, Nocardia spp., and other aerobic actinomycetes. Also included in this standard are recommendations for selecting agents for first-line and second-line drug testing, organism group–specific methodologies, reporting recommendations, and organism quality control criteria.
Read More